| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
107,240,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile LianBio is a biopharmaceutical company. Co. has assembled a pipeline of various product candidates across five different therapeutic areas. Co.'s late-stage development pipeline is led by mavacamten, TP-03 and NBTXR3. Co. develops mavacamten, an oral therapy for the treatment of obstructive hypertrophic cardiomyopathy. Co. has partnered with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 (lotilaner ophthalmic solution), an eye solution for the treatment of Demodex blepharitis. Co. has partnered with Nanobiotix S.A. to develop and commercialize NBTXR3, a radiosensitizer designed to be injected directly into a malignant tumor prior to standard radiotherapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,238,491 |
| Total Buy Value |
$0 |
$0 |
$0 |
$3,054,110 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
5 |
| Total Shares Sold |
0 |
1,731 |
1,731 |
3,970 |
| Total Sell Value |
$0 |
$7,513 |
$7,513 |
$11,215 |
| Total People Sold |
0 |
1 |
1 |
2 |
| Total Sell Transactions |
0 |
1 |
1 |
2 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gu Ehong |
Interim CFO |
• – – |
2024-04-09 |
4 |
D |
$0.32 |
$5,724 |
D/D |
(17,889) |
0 |
|
- |
|
| Silbermann Susan Michele |
Director |
– • – |
2024-02-15 |
4 |
D |
$4.76 |
$91,478 |
D/D |
(19,218) |
17,082 |
|
- |
|
| Silbermann Susan Michele |
Director |
– • – |
2024-02-15 |
4 |
OE |
$2.52 |
$91,476 |
D/D |
36,300 |
36,300 |
|
- |
|
| Edelman Joseph |
Director |
– • • |
2024-02-15 |
4 |
D |
$4.76 |
$182,955 |
I/I |
(38,436) |
17,082 |
|
- |
|
| Edelman Joseph |
Director |
– • • |
2024-02-15 |
4 |
OE |
$2.52 |
$182,952 |
I/I |
72,600 |
36,300 |
|
- |
|
| Poukalov Konstantin |
Director |
– • – |
2024-02-15 |
4 |
D |
$4.76 |
$91,478 |
D/D |
(19,218) |
17,082 |
|
- |
|
| Poukalov Konstantin |
Director |
– • – |
2024-02-15 |
4 |
OE |
$2.52 |
$91,476 |
D/D |
36,300 |
36,300 |
|
- |
|
| Stone Adam Leo |
Interim CEO |
• • – |
2024-02-15 |
4 |
D |
$4.76 |
$91,478 |
D/D |
(19,218) |
17,082 |
|
- |
|
| Stone Adam Leo |
Interim CEO |
• • – |
2024-02-15 |
4 |
OE |
$2.52 |
$91,476 |
D/D |
36,300 |
36,300 |
|
- |
|
| Gianakakos Anastasios |
Director |
– • – |
2024-02-15 |
4 |
D |
$4.76 |
$91,478 |
D/D |
(19,218) |
53,630 |
|
- |
|
| Gianakakos Anastasios |
Director |
– • – |
2024-02-15 |
4 |
OE |
$2.52 |
$91,476 |
D/D |
36,300 |
72,848 |
|
- |
|
| Gu Ehong |
Interim CFO |
• – – |
2024-01-02 |
4 |
S |
$4.34 |
$7,513 |
D/D |
(1,731) |
76,762 |
|
- |
|
| Gu Ehong |
Interim CFOOfficer |
• – – |
2023-12-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
78,493 |
|
- |
|
| Qian Jiang |
SVP, China General Manager |
• – – |
2023-01-03 |
4 |
S |
$1.65 |
$3,702 |
D/D |
(2,239) |
67,349 |
|
- |
|
| Edelman Joseph |
Director |
– • • |
2022-08-18 |
4 |
B |
$2.40 |
$2,395,776 |
I/I |
998,240 |
3,728,491 |
2.25 |
- |
|
| Edelman Joseph |
Director |
– • • |
2022-05-26 |
4 |
B |
$3.13 |
$215,970 |
I/I |
69,000 |
2,730,251 |
2.25 |
- |
|
| Edelman Joseph |
Director |
– • • |
2022-05-25 |
4 |
B |
$2.63 |
$315,600 |
I/I |
120,000 |
2,661,251 |
2.25 |
- |
|
| Edelman Joseph |
Director |
– • • |
2022-05-24 |
4 |
B |
$2.47 |
$105,101 |
I/I |
42,551 |
2,541,251 |
2.25 |
- |
|
| Edelman Joseph |
Director |
– • • |
2022-05-23 |
4 |
B |
$2.49 |
$21,663 |
I/I |
8,700 |
2,498,700 |
2.17 |
- |
|
| Qian Jiang |
China General Manager |
• – – |
2021-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
69,588 |
69,588 |
|
- |
|
| Gianakakos Anastasios |
Director |
– • – |
2021-12-29 |
4 |
OE |
$6.49 |
$237,197 |
D/D |
36,548 |
36,548 |
|
- |
|
| Edelman Joseph |
Director |
– • • |
2021-11-03 |
4 |
B |
$13.51 |
$36,270,200 |
I/I |
2,270,000 |
27,858,895 |
2.25 |
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2021-11-03 |
4 |
A |
$0.00 |
$0 |
I/I |
38,354,515 |
2,477,005 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2021-11-02 |
4 |
B |
$13.50 |
$1,350,000 |
I/I |
100,000 |
7,253,885 |
1.5 |
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2021-11-01 |
4 |
B |
$15.50 |
$1,860,000 |
I/I |
120,000 |
7,153,885 |
1.5 |
- |
|
28 Records found
|
|
Page 1 of 2 |
|
|
